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The surgical treatment of early breast cancer has evolved from the removal of the entire breast and surrounding tissues
(mastectomy) to the removal of the tumour together with a margin of healthy tissue (lumpectomy). Adjuvant radiotherapy,
however, is still mainly given to the whole breast. Furthermore, external beam radiotherapy is often given several months after
initial surgery and requires the patient to attend the radiotherapy centre daily for several weeks. A single fraction of radiotherapy
given during surgery directly to the tumour bed (intraoperative radiotherapy) avoids these problems. The rationale and level-1
evidence for the safety and eﬃcacy of the technique are reviewed.
In 1867, a surgeon at the Middlesex Hospital in London
published a paper providing evidence for the local origin of
breast cancer; after partial removal of the breast, recurrences
were generally near the scar [1]. He thought that the recur-
rences spread centrifugally from the focus through the lym-
phatics, and the best treatment was to remove as much
breast and surrounding tissue as possible. In 1894, Halsted
published the results of a radical mastectomy in 50 patients—
a local recurrence rate of 6%, which was extremely low by the
standards of the time [2]. The technique was adopted enthu-
siastically and developed further with the extended radical
mastectomy (sometimes together with amputation of the
upper arm), culminating in the super-radical mastectomy
[3].
Coincidentally, Wilhelm Ro¨ntgen discovered X-rays in
1895 and the Curies discovered radium in 1898; soon after,
radiation was used to treat breast cancer, with variable results
[4]. However, surgical removal of the whole breast remained
the treatment of choice until the 1970s when results from
trials comparing mastectomy with a combination of breast-
conserving surgery and whole-breast radiotherapy showed
that they were equally eﬀective in terms of survival and
considerably less traumatic for the patient [5]. In addition,
radiotherapy reduced the risk of local recurrence by 75%,
which resulted in a disease-free survival advantage [6] and
indeed overall survival [7].
Currently, postoperative radiotherapy to the whole breast
with a boost to the tumour bed is regarded as an adjuvant
treatment to breast-conserving surgery. However, if the
surgical component of the therapy has moved from whole
breast (mastectomy) to local (lumpectomy), why cannot the
same logic be applied to radiotherapy particularly in this
era of mammography where screen-detected lesions are very
small?
It is interesting to note that pioneering work on local
treatments was performed by Geoﬀrey Keynes, a surgeon at
St Bartholomew’s Hospital in London. In 1922, he experi-
mented with the use of radium encased in hollow platinum
needles that were inserted around the tumour and lymphat-
ics. Keynes combined this local radiotherapy with local exci-
sion (lumpectomy) [8]. Unfortunately, radium was diﬃcult
to obtain and handle, so the technique never caught on.
The results of many observational studies and clinical tri-
als have demonstrated that around 90% of recurrent disease
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Table 1: Summary of evidence regarding the location of in-breast recurrences.
Year Description All LR IBNP True LR Reference
2007 5318 patients with early breast cancer; all had lumpectomy and EBRT ± boost 91 17 81% [36]
1993 567 women ± EBRT, 39mmedian FUP. IBNP “>2 cm from primary site” 25 4 84% [37]
1992 837 women ± EBRT, 43mmedian FUP 131 19 85% [38]
1992 488 women all with lumpectomy plus EBRT, 103m mean FUP. “True”
LR—“at or close to same quadrant as index case”
42 2 95% [39]
1990 783 women, 80m median FUP 91 17 81% [40]
1990 381 women ± EBRT, 30m FUP 15 2 87% [41]
1990 496 women, 71m median FUP 61 15 77% [42]
1990 1593 women, 11 y median FUP 178 38 79% [43]
1989 861 women, 5-6 years median FUP 93 19 80% [44]
1984 231 women, 44m median FUP 12 2 83% [45]
1982 680 women 509 3 >99% [46]
1982 28 women with DCIS treated by biopsy alone, FUP > 3 y 7 1 86% [47]
1981 176 patients, median FUP 47m 15 1 93% [48]
LR = local recurrence (any recurrence in the ipsilateral breast).
IBNP = ipsilateral breast new primary (a LR that is some distance away from the site of the original tumour; precise definitions vary by study).
True LR = (All LR-IBNP)/(All LR) expressed as a percentage.
in the breast after breast conserving surgery is within the
index quadrant, whether or not whole-breast external beam
radiotherapy has been given, see Table 1. Furthermore, after
adjuvant endocrine therapy, the chance of a local recurrence
outside the index quadrant is no more than the risk of a new
contralateral tumour [9].
There is evidence (described below) that ipsilateral breast
cancer recurrence is in fact two distinct diseases, namely:
true recurrence where the cancer is not completely removed
and remaining cells grow to form a recurrence; and a second
primary cancer, a tumour arising independently of the index
tumour. This distinction is important as localised therapy
should be judged on its ability to reduce true recurrences,
but it will not be expected to have an eﬀect on new primary
cancers.
In a retrospective review of 397 patients with ipsilateral
breast tumour recurrence, Yi et al. [10] reported that about
half were classified as new primary cancers by two methods
of assessment using data such as tumour location, histologic
subtype, and hormone receptor status. Patients classified as
having new primary cancers had better outcomes than those
with true local recurrences, specifically 10-year overall and
disease-specific survival rates and likelihood of developing
subsequent metastatic disease. However, they were more
likely to have a contralateral breast cancer.
Komoike et al. [11] described a cohort of 161 Japanese
patients with ipsilateral breast tumour recurrences and clas-
sified them as either true recurrences or new primary can-
cers, based on tumour location and pathological findings.
The true recurrences were associated with a high rate of
lymph node metastases and a shorter disease-free interval
than new primary cancers.
The records of 130 patients with ipsilateral breast tumour
recurrence were reviewed by Smith et al. [12] and classified
as true recurrence if located in the same position from the
primary tumour bed, was of the same histologic subtype, or
had the same DNA flow cytometry (remained aneuploid).
Patients with new primary cancers were found to have better
overall, distant disease-free, and cause-specific survival.
So, it is entirely possible that dormant cancers in the
breast, distant the primary tumour, do not need any inter-
vention. In other words, not all cancers will grow to become
a clinical problem in an individual’s lifetime, a situation
analogous to prostate cancer, where many men die with, but
not of, prostate cancer; men with nonlethal disease do not
benefit from treatment [13]. The evidence to support the
notion of latency amongst microscopic foci of breast cancer
has been well documented [14, 15].
Whole-breast radiotherapy is not without risk. Treat-
ment regimens have become safer since the identification
of long-term side eﬀects such as increased mortality from
myocardial infarction after radiotherapy for left-sided breast
cancer [16]. But, no matter how carefully applied, healthy
tissues such as the heart, ribs, and lungs do receive a dose
of radiation.
Other issues with whole-breast radiotherapy include the
following.
(i) The fractionated doses take between 3 and 7 weeks
to deliver, which is a great inconvenience for women
who work or look after grandchildren or ill adults or
for the elderly who find the daily journeys exhausting.
Women in the developing world or those in wealthy
countries who live in rural areas more than 100 miles
from a centre are denied the chance of breast-
conserving surgery and must have a mastectomy, or
else are at great hazard of local recurrence if the
treatment is omitted [17, 18].
(ii) The radiotherapy equipment is expensive to purchase
and to run and requires installation in a shielded
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building. In the UK, the treatment of breast cancer
accounts for approximately a third of the workload
of radiotherapy departments.
(iii) Geographic misses are commonplace in postopera-
tive attempts to target the tumour bed [19].
(iv) Cosmesis is often impaired by the short- or long-term
radiotoxicity.
(v) Delays in the start of chemotherapy or delays in
the start of radiotherapy in order to accommodate
chemotherapy might compromise either modality
[20]. A delay of over six weeks has been shown to
significantly increase the risk of recurrence at 5 years
[21].
Risks associated with accelerated partial breast irradi-
ation include persistent seroma, postprocedural infection,
erythema, telangiectasia, edema, blistering, skin thickening,
fibrosis, tenderness, and pain; in general, these toxicities are
modest and acceptable [22, 23].
Clinicians are increasingly adopting the view that per-
haps it is not necessary to irradiate the whole breast, but
rather to restrict treatment to the immediate area around
the tumour bed or index quadrant. Accelerated partial
breast irradiation (APBI) aims to decrease the volume of
breast treated and increase the daily fraction size of radi-
ation so that the entire dose can be delivered within 1
week (instead of 3–7 weeks). Techniques include linac-
based intensity-modulated radiotherapy, multicatheter inter-
stitial brachytherapy, balloon-based APBI using the Mam-
moSite brachytherapy applicator (Hologic, Inc., Mass, USA),
and a newly developed, modified form of balloon-based
brachytherapy called Xoft Axxent Electronic Brachytherapy
(Xoft, Inc., Calif, USA). A review of randomised trials and
prospective single-arm studies led the American Society
for Therapeutic Radiation Oncology to issue a consensus
statement regarding groups of patients who could be treated
by APBI, while urging that further research was required
[24].
There are currently seven ongoing randomized trials
testing various methods of APBI against whole-breast radio-
therapy [25]. However, they are not comparable since they
vary in inclusion criteria, total dose, fractionation, volume,
and timing related to chemotherapy and hormone treatment.
The National Surgical Adjuvant Breast and Bowel Project
and the Radiation Therapy Oncology Group have noted
this shortcoming which is being addressed in an intergroup
study randomising patients with early-stage breast cancer to
whole-breast irradiation versus APBI (using either interstitial
brachytherapy, Mammosite balloon catheter, or 3D confor-
mal external beam); accrual is expected to be completed soon
(NSABP B-39/RTOG 0413, [26]).
There is, however, one type of APBI that has already
generated level-1 evidence—intraoperative radiotherapy
(IORT) given as a single fraction to the tumour bed during
surgery.
The technique of IORT using INTRABEAM (Carl Zeiss
Surgical, Oberkochen, Germany), termed TARGIT, was
pioneered in London [27] and allows the patient to receive
a single fraction of radiotherapy as soon as the primary
tumour is excised, during the same anaesthetic. Advantages
of this approach include delivering the radiation immedi-
ately, ensuring the radiation is delivered to the tumour bed
under direct vision, thus avoiding a “geographical miss”, and
decreasing costs to the healthcare providers.
INTRABEAM is a mobile, miniature X-ray generator
powered by a 12-volt supply. Accelerated electrons strike
a gold target at the tip of a 10 cm long drift tube with a
diameter of 3mm, resulting in the emission of low-energy
X-rays (50 kV) in an isotropic dose distribution around the
tip. The irradiated tissue is kept at a fixed, known distance
from the source by spherical applicators to ensure a more
uniform dose distribution. The tip of the electron drift tube
sits precisely at the epicentre of a spherical plastic applicator,
the size of which is chosen to fit the cavity after the tumour
is excised, see Figure 1. Using this method, the walls of the
tumour cavity are irradiated with a biologically eﬀective dose
(20Gy to the tissue in contact with the applicator) that
rapidly attenuates over a distance of a few centimetres. As
a result, healthy tissue such as the vital organs is spared and
the device can be used in an unmodified operating theatre as
there is no need for lead shielding [27].
Another IORT approach is electron intraoperative ther-
apy, pioneered at the European Institute of Oncology in
Milan, Italy. In this technique, a portable linear accelerator
is used to deliver a single dose of 21Gy radiation during the
surgery [28]. With this approach, it is necessary to perform
the procedure in a specially shielded operating theatre for
radiation safety considerations. The technique is currently
being tested in a clinical trial, and results are eagerly awaited,
as results from associated studies look promising [28, 29].
The safety and tolerability of the TARGIT technique has
been established in a phase II study [30]. Starting in 1998,
all 299 patients (with 300 cancers) who underwent breast
conserving surgery for their breast cancer management
received a single 20Gy dose of radiotherapy during surgery.
In these patients, this replaced 1 week of radiation to the
tumour bed (boost radiation), and all patients received stan-
dard external beam radiotherapy to the whole-breast. A
total of 32% of the patients were younger than 51 years;
57% of cancers were between 1 and 2 cm (21% >2 cm);
29% had a grade 3 tumour; 27% were node positive. The
treatment was well tolerated by all patients, and with median
followup of 60.5 months (range: 10–120 months), eight
patients had developed ipsilateral recurrence: the 5-year
Kaplan-Meier estimate for ipsilateral recurrence is 1.74%
(standard error: 0.77). Based on the success of this study, a
phase III superiority trial comparing TARGIT boost versus
conventional boost will soon be launched.
In March 2000, an international, randomized controlled
trial was launched comparing TARGIT versus whole breast
external beam radiotherapy as a noninferiority study with
the primary outcome of local recurrence. The original
recruitment goal of 2232 (powered to test noninferiority;
hazard ratio <1.25) was reached in early 2010, and the results
were published [31]. 1113 patients were randomly allocated
to TARGIT and 1119 to external beam radiotherapy. 14% of
the TARGIT group also received external beam radiotherapy.
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Figure 1: (a) The portable X-ray accelerator (Intrabeam). Soft X-rays are produced at the tip of the drift tube. (b) The intrabeam device
mounted on the stand. The unit is portable and can be moved into the operating theatre as and when required. (c) Sterile drape and
applicator in place, ready for positioning by the surgeon. (d) The applicator has been placed in the tumour bed and a purse-string suture is
being applied to ensure conformity of the tissue to the applicator.
At 4 years, there were six local recurrences in the TARGIT
group and five in the external beam radiotherapy group. The
Kaplan-Meier estimate of local recurrence in the conserved
breast at 4 years was 1.20% (95% CI 0.53–2.71) after
TARGIT compared with 0.95% (0.39–2.31) in the external
beam radiotherapy group; the diﬀerence between the groups
was not significant. The frequency of any complications
and major toxicity was similar in the two groups, and
radiotherapy toxicity was lower in the TARGIT group.
The results of this study provide level-1 evidence that, for
selected patients with early breast cancer, a single dose of
radiotherapy delivered at the time of surgery using the
TARGIT technique should be considered as an alternative to
external beam radiotherapy delivered over several weeks.
Recruitment to the TARGIT Trial has been extended
primarily to allow completion of subprotocols (quality of life,
patient preference, health economics, and cosmesis). A pilot
of the cosmesis subprotocol in 118 patients indicated a supe-
rior cosmetic outcome in the first year for those receiving
TARGIT [32]. Results from a pilot patient preference study of
58 patients were used to determine if patients would accept
the additional risk of 10-year recurrence in order to have
TARGIT instead of conventional external beam radiotherapy.
54 (93%) of the subjects said they would undergo TARGIT if
it oﬀered equivalent or some added risk compared to EBRT
[33].
Not all patients with early breast cancer were suitable
for inclusion in the TARGIT Trial. In three major centres in
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the UK, Germany, and Australia, we oﬀered IORT oﬀ-trial
to a highly selected group of 80 patients with exceptional
circumstances who could not receive standard external
beam radiotherapy. Reasons for using TARGIT included 21
patients who had in-breast tumour recurrence in previously
irradiated breasts, and 31 patients had clinical reasons such
as systemic lupus erythematosus, motor neuron disease,
Parkinson’s disease, ankylosing spondylitis, morbid obesity,
and cardiovascular or severe respiratory disease. 28 patients
were included for compelling personal reasons, usually on
compassionate grounds. After a median followup of 38
months, only two local recurrences were observed, which is
an annual local recurrence rate of 0.75% (95% confidence
interval, 0.09%–2.70%). These results indicate that TARGIT
provides acceptable toxicity and good local control and oﬀers
an alternative to mastectomy in highly selected cases in
whom conventional radiotherapy is not feasible or possible
[34].
It has been found that wound fluid (taken from the drain
over the first 24 h after surgery) stimulated proliferation,
migration, and invasion of breast cancer cell lines; however,
the stimulatory eﬀect almost completely disappeared when
fluids from TARGIT-treated patients were used. This was due
to an alteration in the molecular composition and biological
activity of the wound fluid and could provide some explana-
tion for the very low recurrence rates found using TARGIT
[35].
In summary, the evidence is mounting for TARGIT to
replace whole-breast external beam radiotherapy for selected
patients with early breast cancer. The technique is relatively
easy to use, does not require shielding of the operating
theatre, and largely protects healthy tissues. Furthermore,
TARGIT is suitable for developing countries—an unusual
example where a new health technology is more aﬀordable
than the existing standard and can optimise treatment and
reduce the number of unnecessary mastectomies.
Looking forward, these encouraging results have pro-
mpted the initiation of new clinical trials using the TARGIT
technique, for example, as the sole radiotherapy treatment
in elderly women where long-term outcomes are less of a
consideration; in nipple-sparing mastectomy to treat residual
breast tissue behind the nipple-areolar complex; in cases of
screen-detected DCIS with small focal lesions.
The treatment of breast cancer has undergone an evo-
lution and is now poised for a revolution. New adjuvant
hormonal therapies, novel chemotherapy, and targeted bio-
logical therapies are all helping to drive down mortality
rates, and as this happens, cost eﬀectiveness and patient
acceptability become relatively more important. The radical
approach of radiotherapy in early breast cancer is now being
questioned. If IORT proves to be a suitable replacement
for external beam radiotherapy, then many women will be
spared several weeks of travelling back and forth to the
radiotherapy centre.
Furthermore, tens of thousands of women in the devel-
oping world who live hundreds of miles from a radiotherapy
unit, or in countries that cannot aﬀord the multimillion
pound investment, will be able to enjoy the advantages of
breast conservation instead of having to undergo mastec-
tomy.
The quest for the optimal treatment for early breast can-
cer has come a long way in the past 100 years or so. New tech-
nology, rigorously tested, will enable us to go a lot further.
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